Literature DB >> 26122768

Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness.

Maxime Pichette1, Florent Chevalier1, Philippe Généreux1,2.   

Abstract

Everolimus-eluting bioresorbable vascular scaffolds (BVS) have emerged as an alternative to conventional metallic stents and have demonstrated favorable outcomes in simple coronary lesions. As the use of BVS increases and extends to more complex lesion subsets, intraprocedural complications are expected to occur. We describe for the first time the occurrence of a free coronary perforation localized at the exact point of overlap of two BVS. This case illustrates the importance of appropriate vessel sizing, especially when BVS overlapping is performed in a small vessel, and potential advantages of scaffold juxtaposition compared to overlapping when implanting BVS in series.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  bioresorbable vascular scaffolds; coronary artery perforation; overlap

Mesh:

Year:  2015        PMID: 26122768     DOI: 10.1002/ccd.26055

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

Review 1.  BRS implantation in long lesions requiring device overlapping: myth or reality?

Authors:  Simone Biscaglia; Andrea Erriquez; Davide Bernucci; Giulia Bugani; Enrico Favaretto; Gianluca Campo
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis.

Authors:  Le Ni; Hao Chen; Zhurong Luo; Yunqiang Yu
Journal:  J Cardiothorac Surg       Date:  2020-01-28       Impact factor: 1.637

3.  Coronary artery perforation after bioresorbable scaffold implantation treated with a new generation covered stent-OCT insights.

Authors:  D Chen; R Gadeley; A Wang; N Jepson
Journal:  BMC Cardiovasc Disord       Date:  2022-02-23       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.